Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 19/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 19/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 19/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 19/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 19/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 18/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 15/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 11/20 | 1.00 |
| ▸ | GABRP | O00591 | 6/20 | 1.00 |
| ▸ | GABRD | O14764 | 6/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 6/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 6/20 | 1.00 |
| ▸ | GABRE | P78334 | 6/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 6/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | PDE5A | O76074 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29635240 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| Beta-Ccm SCHEMBL1066725 | 0.85 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| Beta-Ccm SCHEMBL30480071 | 0.85 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| Beta-Ccm SCHEMBL28185000 | 0.84 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL17517484 | 0.84 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL29672619 | 0.82 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL30274389 | 0.82 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL601711 | 0.82 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8845187 | 0.82 | GABRA1 (0.78) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL10857122 | 0.80 | GABRA1 (0.75) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260846-A1 | Novel methods for the treatment of cancer | Lankenau Institute for Medical Research (US) | 2010-12-15 | — | — | EP | claimed |
| EP-1606285-A4 | NOVEL IDO INHIBITORS AND METHODS OF USE | LANKENAU INST MEDICAL RES (US) | 2009-03-18 | — | — | EP | claimed |
| EP-1613308-A4 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INST MEDICAL RES (US) | 2008-02-20 | — | — | EP | claimed |
| US-20070173524-A1 | \"Novel ido inhibitors and methods of use | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-07-26 | — | — | US | claimed |
| US-20070099844-A1 | Novel methods for the treatment of cancer | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-03 | — | — | US | claimed |
| EP-1613308-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | Lankenau Institute for Medical Research (US) | 2006-01-11 | — | — | EP | claimed |
| EP-1606285-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE | Lankenau Institute for Medical Research (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004094409-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2004-11-04 | — | — | WO | claimed |
| WO-2004093871-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2004-11-04 | — | — | WO | claimed |
| US-10835513-B2 | Methods and treatments for the learning and memory deficits associated with Noonan syndrome | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200316087-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2020-10-08 | — | — | US | disclosed |
| US-20200085790-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2020-03-19 | — | — | US | disclosed |
| WO-2019070910-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | UWM RESEARCH FOUNDATION, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| EP-2260846-B1 | Novel methods for the treatment of cancer | LANKENAU INST MEDICAL RES (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20070099844-A1 | Novel methods for the treatment of cancer | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-03 | — | — | US | disclosed |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-11-16 | — | — | US | disclosed |
| EP-1613308-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | Lankenau Institute for Medical Research (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005120496-A2 | TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2004093871-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20030176456-A1 | Methods for reducing alcohol cravings in chronic alcoholics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173524-A1 | \"Novel ido inhibitors and methods of use | IDO1, IDO2, INMT | GABRA1 3846/4885GABRG2 3501/4885GABRB3 2794/4885 |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | GABRA5, GABRA6, GABRA1 | GABRA1 3/4885GABRG2 16/4885GABRB3 10/4885 |
| US-20200316087-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | GABRB2, GABRB1, GABRB3 | GABRA1 5/4885GABRG2 11/4885GABRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.